The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Open accessAbstract
MUC1 is a highly attractive immunotherapeutic target owing to increased expression, altered glycosylation, and loss of polarity in >80% of human cancers. To exploit this, we have constructed a panel of chimeric Ag receptors (CAR) that bind selectively to tumor-associated MUC1. Two parameters proved crucial in optimizing the CAR ectodomain. First, we observed that the binding of CAR-grafted T cells to anchored MUC1 is subject to steric hindrance, independent of glycosylation status. This was overcome by insertion of the flexible and elongated hinge found in immunoglobulins of the IgD isotype. Second, CAR function was highly dependent upon strong binding capacity across a broad range of tumor-associated MUC1 glycoforms. This was realized by using an Ab-derived single-chain variable fragment (scFv) cloned from the HMFG2 hybridoma. To optimize CAR signaling, tripartite endodomains were constructed. Ultimately, this iterative design process yielded a potent receptor termed HOX that contains a fused CD28/OX40/CD3ζ endodomain. HOX-expressing T cells proliferate vigorously upon repeated encounter with soluble or membrane-associated MUC1, mediate production of proinflammatory cytokines (IFN-γ and IL-17), and elicit brisk killing of MUC1+ tumor cells. To test function in vivo, a tumor xenograft model was derived using MDA-MB-435 cells engineered to coexpress MUC1 and luciferase. Mice bearing an established tumor were treated i.p. with a single dose of engineered T cells. Compared with control mice, this treatment resulted in a significant delay in tumor growth as measured by serial bioluminescence imaging. Together, these data demonstrate for the first time that the near-ubiquitous MUC1 tumor Ag can be targeted using CAR-grafted T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis
Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., & Iwakura, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.566 · Cited by 1,536
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Self-citationLamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Hilkens, J., Buijs, F., Hilgers, J., Hageman, P., Calafat, J., Sonnenberg, A., & Van Vlak, M. D. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910340210 · Cited by 488
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Current Progress in CAR-T Cell Therapy for Solid Tumors
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.34213 · Cited by 496
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Self-citationMesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 477
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Engineering and Design of Chimeric Antigen Receptors
Guedan, S., Calderon, H., Posey, A. D., & Maus, M. V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.009 · Cited by 453
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D., & Brentjens, R. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10940-8 · Cited by 409
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Y., Klein Wolterink, R. G. J., Wang, J., Bos, G. M. J., & Germeraad, W. T. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01083-5 · Cited by 379
CAR-T design: Elements and their synergistic function
Jayaraman, J., Mellody, M. P., Hou, A. J., Desai, R. P., Fung, A. W., Pham, A. H. T., Chen, Y. Y., & Zhao, W. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102931 · Cited by 374
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Dai, H., Wang, Y., Lu, X., & Han, W. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv439 · Cited by 299
Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817147116 · Cited by 296
van der Stegen, S. J. C., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301523 · Cited by 126
Self-citationYu, L., Li, Z., Mei, H., Li, W., Chen, D., Liu, L., Zhang, Z., Sun, Y., Song, F., Chen, W., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1248 · Cited by 113
Metadata
- Authors
- Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., & Maher, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04-01
- Volume
- 180
- Issue
- 7
- Pages
- 4901-4909
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1623064933
- Cited by
- 346
- References
- 38
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.